I'd like to compare BRN with biotech. Lots of companies are in development stage without revenue. Their MC is way above $1B. If successful they get bought out for several $B. From what I understand BRN can be compared with a biotech company in phase III of their development. Many companies get bought out either earlier or when phase III is finished and the product gets FDA approval. Depending on the addressable market and its positioning (meaning "first to market", much better efficacy, years ahead of competition), such biotech companies get bought out on the high side.
Under the assumption that BRN is just finishing its "phase III" with a high probability to be successful and of what we know so far, the MC is not too high in comparison. Nevertheless, the ride from 30c to 73c in just a few months is staggering and nothing is guaranteed. So let us keep our fingers crossed and enjoy the journey.
1.138B MCAP? I don't think so, page-54
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BRN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $451.3M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.0¢ | 21.5¢ | $2.863M | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 136498 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 444756 | 13 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| BRN (ASX) Chart |